Us Congress 2023-2024 Regular Session

Us Congress House Bill HB447

Introduced
1/24/23  

Caption

Medical Manufacturing, Economic Development, and Sustainability Act of 2023 or the MMEDS Act of 2023 This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical manufacturers. The bill increases the credit rate for minority businesses.

Impact

The implications of HB 447 are significant for state laws concerning economic development and healthcare. By providing substantial financial incentives for medical manufacturers, the bill aims to stimulate job creation in areas suffering from high unemployment and poverty rates. The designation of 'economically distressed zones' will facilitate targeted investments in regions that need economic rejuvenation. Furthermore, the bill encourages collaboration between state and local officials to develop strategic plans to leverage these incentives effectively.

Summary

House Bill 447, titled the 'Medical Manufacturing, Economic Development, and Sustainability Act of 2023' or the 'MMEDS Act of 2023', focuses on revitalizing medical manufacturing in the United States, particularly in economically distressed areas. The bill proposes various tax incentives aimed at encouraging the establishment and expansion of medical manufacturing facilities. Notably, it includes a tax credit of 40% on wages paid, employee benefit expenses, and depreciation on facilities dedicated to medical production located within these distressed zones. This is part of a broader strategy to strengthen the domestic medical manufacturing sector and enhance national supply chain stability.

Contention

Several points of contention arise from the provisions of HB 447. Critics may argue that incentivizing businesses to relocate or expand in economically distressed areas should come with stringent guidelines to ensure that such actions do not lead to negative employment shifts in other regions. Additionally, while the bill aims to support minority-owned businesses by increasing the credit rate for services acquired from such entities, there could be concerns about whether these incentives are adequate to truly address systemic inequities faced by these businesses. Lastly, the effective implementation of this bill will rely heavily on state-level regulatory frameworks to define the scope and criteria for determining economically distressed zones.

Companion Bills

No companion bills found.

Similar Bills

US SB33

Medical Manufacturing, Economic Development, and Sustainability Act of 2023 or the MMEDS Act of 2023 This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical product manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical product manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical product manufacturers.. The bill also directs the Department of Health and Human Services to study the extent to which the health of aging individuals and vulnerable populations have been disproportionately harmed by the COVID-19 (i.e., coronavirus disease 2019) pandemic and prior epidemics and pandemics.

US HB405

Essential Medicines Strategic Stockpile Act of 2023 This bill requires the Department of Health and Human Services (HHS) to create a pilot program to test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile of generic drugs at risk of shortage. To carry out the pilot program, HHS must enter into contracts for a term of up to three years with drug manufacturers, co-op or chain pharmacy warehouses, or other eligible entities to create a six-month stockpile of up to 50 types of such drugs. The bill establishes various program requirements, including annual evaluations by the Government Accountability Office.

US HB62

Safeguard Healthcare Industry Employees from Litigation and Distress Act or the SHIELD Act This bill establishes a framework to limit interference with persons seeking to provide or access reproductive health services at the state level. For the purposes of this summary, interference with persons seeking to provide or access reproductive health services includes acts to prevent, restrict, impede, or retaliate against a health care provider who provides reproductive health care services, any person or entity who helps health care providers to provide such services, any person who seeks to access such services, or any person or entity who helps another person to access such services. First, the bill reduces the allocation of funds under certain law enforcement grant programs for a state that has in effect a law authorizing state or local officers or employees to interfere with persons seeking to provide or access reproductive health services. Second, the bill prohibits interference with persons seeking to provide or access reproductive health care services by state or local officers or employees acting under color of law in any manner that would have a discriminatory effect on a woman, and by persons who are not state or local officers or employees and are attempting to implement or enforce a state law in circumstances affecting interstate commerce. The bill authorizes civil remedies for a violation, including damages and injunctive relief. Additionally, it authorizes criminal penalties for a violation involving the use of a deadly or dangerous weapon or the infliction of bodily injury.

US SB25

Assault Weapons Ban of 2023 This bill makes it a crime to knowingly import, sell, manufacture, transfer, or possess a semiautomatic assault weapon (SAW) or large capacity ammunition feeding device (LCAFD). The prohibition does not apply to a firearm that is (1) manually operated by bolt, pump, lever, or slide action, except for certain shotguns; (2) permanently inoperable; (3) an antique; (4) only capable of firing rimfire ammunition; or (5) a rifle or shotgun specifically identified by make and model. The bill also exempts from the prohibition the following, with respect to a SAW or LCAFD: importation, sale, manufacture, transfer, or possession related to certain law enforcement efforts, or authorized tests or experiments; importation, sale, transfer, or possession related to securing nuclear materials; and possession by a retired law enforcement officer. The bill permits continued possession, sale, or transfer of a grandfathered SAW, which must be securely stored. A licensed gun dealer must conduct a background check prior to the sale or transfer of a grandfathered SAW between private parties. The bill permits continued possession of, but prohibits sale or transfer of, a grandfathered LCAFD. Newly manufactured LCAFDs must display serial number identification. Newly manufactured SAWs and LCAFDs must display the date of manufacture. The bill also allows a state or local government to use Edward Byrne Memorial Justice Assistance Grant Program funds to compensate individuals who surrender a SAW or LCAFD under a buy-back program.

US SB34

Facilitating the Reshoring of Energy Grid Component Manufacturing Act of 2023 This bill directs the Department of Energy (DOE) to establish a loan program for the production of energy grid products or components. Under the program, DOE may provide loans for activities related to projects that reequip, expand, or establish manufacturing facilities to produce energy grid products or their components. Energy grid products include large power transformers or any other electrical equipment commonly used for the transmission or distribution of electric energy by public electric utilities.

US HB8

Drug Pricing Transparency and Accountability Act

US HB204

Drug Testing for Welfare Recipients Act This bill requires the Temporary Assistance for Needy Families program, the Supplemental Nutrition Assistance Program, and specified public housing programs to subject individuals to substance-abuse screening and to deny benefits for individuals who test positive for a controlled substance.

US HB170

Domestic Security Using Production Partnerships and Lessons from Yesterday Act of 2023 or the Domestic SUPPLY Act of 2023 This bill establishes a program and sets out other requirements to promote domestic manufacturing of personal protective equipment (PPE) for infectious diseases and other public health emergencies. The Department of Health and Human Services (HHS) must establish a program to enter into purchasing agreements for PPE produced domestically by manufacturers that are majority-owned and -operated by U.S. citizens. HHS must coordinate with the Department of Defense and the Department of Homeland Security on this program. In addition, the federal government must only procure, subject to limited exceptions, PPE that is produced domestically to prevent the transmission of an infectious disease. If using federal funds, states or localities must also procure PPE domestically. Further, the bill requires HHS to consult with the Occupational Safety and Health Administration on a report about changes to federal requirements for PPE during the COVID-19 pandemic and the impact of those changes on health care workers who cared for patients in 2020 and 2021.